- Home
- MOB vs KZIA Comparison
MOB vs KZIA Comparison
Compare MOB & KZIA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | MOB | KZIA |
|---|---|---|
| Founded | 2008 | 1994 |
| Country | Israel | Australia |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 84.0M | 74.1M |
| IPO Year | N/A | 2002 |
Fundamental Metrics
Financial Performance| Metric | MOB | KZIA |
|---|---|---|
| Price | $5.45 | $8.25 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 3 |
| Target Price | $10.00 | ★ $17.67 |
| AVG Volume (30 Days) | ★ 405.7K | 194.6K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $94.62 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.31 | $0.64 |
| 52 Week High | $11.01 | $17.40 |
Technical Indicators
Market Signals| Indicator | MOB | KZIA |
|---|---|---|
| Relative Strength Index (RSI) | 43.51 | 64.10 |
| Support Level | $3.62 | $5.64 |
| Resistance Level | $6.60 | $8.94 |
| Average True Range (ATR) | 0.56 | 0.78 |
| MACD | 0.03 | 0.41 |
| Stochastic Oscillator | 32.49 | 85.66 |
Price Performance
Historical ComparisonAbout MOB Mobilicom Limited
Mobilicom Ltd is a provider of cybersecurity and smart solutions for drones, robotics & autonomous platforms. As a high-tech company, it designs, develops, and delivers smart solutions targeting global drone, robotics, and autonomous system manufacturers. Its products include OS3 Platform Software, ICE Cybersecurity Software, MCU Mesh Networking, SkyHopper Datalinks, Mobile Ground Control Stations and System Engineering Services.
About KZIA Kazia Therapeutics Limited
Kazia Therapeutics Ltd is a biotechnology company focused on pharmaceutical drug development in oncology. The company has a portfolio of development candidates across various technologies targeting multiple cancer indications. Its primary program is Paxalisib, an investigational brain-penetrant inhibitor of the PI3K/Akt/mTOR pathway, designed for the treatment of brain cancer. The company develops targeted therapies aimed at addressing medical needs in oncology. The company operates in Australia and the United States.